Xu and colleagues, in their analysis of the prognostic importance of LDH levels in melanoma patients undergoing anti-PD-1/PD-L1 monotherapy, concluded that LDH levels could serve as a potential prognostic biomarker for anti-PD-1/PD-L1 therapy in melanoma patients [51]. This evidence concerns the gene CD274 and melanoma.